Rituximab for treatment of ocular inflammatory disease: a series of four cases.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 19321476.
- Also identified by DOI 10.1136/bjo.2007.133173.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Rituximab may be effective in the treatment of ocular inflammatory disease. Dosing is less frequent than many medications currently available. Four cases are reported, each of which appeared to have responded well to treatment with rituximab, although patient 2 was able to remain on a low dose of prednisone for only 2 months. The ongoing pilot study will hopefully provide additional insight into the benefit of rituximab for treatment of scleritis and idiopathic orbital inflammatory disease.
Medical subject headings
- Antibodies, Monoclonal
- Immunologic Factors
- Orbital Diseases
- Scleritis